From Dealroom · · 50s
Durham's Incyclix Bio Raises $52M for Gentler Cancer Therapies
Incyclix Bio secures $52M to develop less toxic cancer treatments for breast and ovarian cancers.
In brief
Incyclix Bio secures $52M to develop less toxic cancer treatments for breast and ovarian cancers. Incyclix Bio raised $52 million for precision cancer therapies targeting resistance to existing treatments. Originally reported by Dealroom.
New Funding Round
Durham-based Incyclix Bio raised $52 million in a late-stage venture round to advance precision treatments for breast and ovarian cancers now in clinical trials.
Drug Development
The biotech, founded in 2020 by Patrick Roberts, Jay Strum, and John Bisi, is developing CDK2 inhibitors to curb tumor growth with fewer side effects than traditional chemotherapy.
Lead Drug
Its lead drug, INX 315, adds a CDK2 inhibitor on top of existing treatments to overcome resistance that lets cancer return.
Clinical Trials
INX 315 is in trials across 19 hospitals targeting patients whose breast or ovarian cancer progressed despite earlier CDK4/6 treatment.
The big picture
Incyclix Bio raised $52 million for precision cancer therapies targeting resistance to existing treatments.
